In recent years, China has attached great importance to the innovation of the pharmaceutical industry, and the introduction of a series of related policies has accelerated the rapid development of the industry. Data shows that the size of pharmaceutical market of China reached 137 billion US dollars in 2018, a four-fold increase over 10 years, and it is expected to reach 170 billion US dollars in 2023. The Chinese pharmaceutical market has formed a competitive landscape in which "multinational pharmaceutical companies are actively transforming, traditional pharmaceutical companies are seeking transformation, and innovative pharmaceutical companies are rapidly emerging." Under this pattern, open innovation has become the consensus of the industry development. Pharmaceutical companies seek to increase their R&D efficiency and reduce costs by seeking external partners to enhance their competitiveness. Along with this, there are more and more project cooperation, in- and out-licensing, investment and M&A between multinational pharmaceutical companies, traditional pharmaceutical companies and innovative pharmaceutical companies. In addition, the pharmaceutical industry has been the focus of venture capital. Under the influence of Covid-19, investment in pharmaceutical will receive more attention, more and more capital will flow into this field.

Based on this background, 2nd China Pharma Due Diligence Conference will be held in Shanghai on September 28-29, 2022 (we hold the 1st China Pharma Due Diligence Conference 2020 on Nov. 19-21 in Shanghai). We will invite pharmaceutical / biotechnology company, venture capital, law firms, account firm and consulting firm to participate to discuss due diligence issues on investment, M&A, business development and licensing, IPO and financing, partnering.